NCT06925854

A Study to Investigate How AZD4144 Affects the Pharmacokinetics of Rosuvastatin in Healthy Participants

An Open-label, 2-period, 2-sequence Cross-over Study to Assess the Effect of AZD4144 on the Pharmacokinetics of Rosuvastatin in Healthy Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the pharmacokinetics (PK) of rosuvastatin when administered alone and in combination with single oral dose of AZD4144.

Detailed description

This is a Phase 1, randomized, open label study in healthy participants. The participants will be provided with: Treatment A: single dose of rosuvastatin Treatment B: single dose of rosuvastatin in combination with AZD4144. The participants will be randomized in the 1:1 ratio to either receive treatment sequence AB or sequence BA. The study will be comprised of: * A screening period of 28 days. * Two treatment periods (Treatment period 1 and Treatment period 2) of 4 days each where participants will receive the study intervention on Day 1 in Treatment period 1 and on Day 10 in Treatment period 2. * A final Follow-up visit between Day 17 and Day 20.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	AZD4144	Oral tablet of AZD4144 will be administered.
DRUG	Rosuvastatin	Oral tablet of rosuvastatin will be administered.

Timeline

• Start date: 2025-04-17
• Primary completion: 2025-06-12
• Completion: 2025-06-12
• First posted: 2025-04-13
• Last updated: 2025-06-18

Locations

1 site across 1 country: United Kingdom